I have spent nine years working within and around the National Health Service (NHS)—the UK’s publicly funded healthcare system—and if there is one thing I have learned, it is that clinical culture moves slowly. For a long time, the mention of cannabis in a medical setting was a non-starter. It was a fringe topic, often conflated with recreational use, and rarely afforded the same evidence-focused talk as a new pharmaceutical treatment.
That has changed. Since the legislative shifts of 2018, we have seen a noticeable move toward treating Cannabis-Based Products for Medicinal use (CBPM) as a legitimate, albeit highly regulated, therapeutic option. But are we actually discussing it more clinically? The short answer is yes. The long answer involves a complex web of digital infrastructure, private healthcare growth, and a significant cultural shift in how we approach patient history.
The 2018 Legalization: A Starting Point, Not a Finish Line
In November 2018, the UK government moved cannabis from Schedule 1 to Schedule 2 under the Misuse of Drugs Regulations 2018. This change meant that specialist doctors could legally prescribe CBPMs for specific conditions. Before this, these products were effectively inaccessible outside of rare, highly publicized compassionate access cases.
However, many patients misunderstood this as "legalization for everyone." It was not. It was a narrow opening for specialist prescribing. This created an immediate disconnect between public perception—which expected wide availability—and the clinical reality, which required rigorous evidence to support each prescription.
The NHS and the Cautionary Path
The NHS has been incredibly cautious. Following the 2018 change, the National Institute for Health and Care Excellence (NICE), the body responsible for providing national guidance on health, reviewed the evidence base for cannabis. They found that for many conditions, the evidence was not yet strong enough to justify widespread NHS prescribing. Consequently, NHS prescribing for CBPM remains extremely limited, usually restricted to a small number of specialist centers for conditions like severe epilepsy or MS-related spasticity.
Here is what usually happens next: A patient approaches their GP (General Practitioner) seeking access to medical cannabis, only to be told that the GP is not a specialist and cannot legally initiate that prescription. This is where the gap between NHS capacity and patient need began to widen, paving the way for the private sector.
The Rise of Private Telehealth Platforms
As the NHS remained cautious, a new ecosystem of private clinics emerged. These clinics were early adopters of digital-first healthcare. By utilizing Telehealth platforms, these clinics bypassed the geographical barriers that previously limited access to specialist care.
For patients, the transition to digital has been profound. A patient in rural Cornwall can now have a video consultation with a specialist in London. This shift is not just about convenience; it is about standardizing a process that was previously opaque. These digital workflows ensure that every step—from initial screening to specialist review—is documented, audited, and strictly compliant with clinical governance.
The Workflow: How Digital Clinics Operate
Modern clinics have adopted a digital-first approach to manage patient safety. The workflow typically looks like this:
Screening: Initial digital questionnaires to ensure the patient has tried first-line treatments. Records Review: Specialists examine medical history, usually requested from the patient’s GP. Video Consultations: A formal, recorded interaction where the specialist assesses the suitability of CBPM. MDT Review: The Multi-Disciplinary Team (MDT) meets to discuss the patient’s case before a prescription is approved.The Cultural Shift: From Stigma to Healthcare Framing
The most significant change I have witnessed is the language. A few years ago, cannabis discussions were dominated by anecdotes about "miracle relief"—a phrase I avoid entirely because it overpromises and undersells the complex reality of chronic condition management. Today, the conversation is shifting toward healthcare framing. We talk about titrating doses, monitoring side effects, and looking at patient-reported outcome measures.
This is evidence-focused talk. It treats cannabis as a medication, not a lifestyle choice. By engaging in these clinical conversations, we are slowly stripping away the stigma that prevented honest communication between patients and clinicians for decades.
Things Patients Wish They Knew Before the First Video Consult
Based on my interviews with clinic staff and patients, here is a running list of realities that newcomers often miss:
- Your GP records are essential: The specialist needs to see that you have exhausted traditional treatments first. It is not a "cure-all": Be prepared to discuss specific symptoms rather than vague notions of general relief. Be clear about your history: Any history of psychosis or substance misuse will be discussed openly and clinically. Video Consultations are clinical, not casual: Dress and prepare as you would for an in-person appointment. Cost is a reality: Private access is funded by the patient; ask for a full breakdown of consultation and medication costs upfront.
NHS vs. Private Pathways: A Quick Comparison
To help you navigate these options, consider the following differences in how these pathways currently function.
Feature NHS Pathway Private Pathway Availability Extremely Limited Widely Available (for eligible conditions) Cost Covered by the state Self-funded by patient Access Speed Very slow (years of review) Fast (weeks) Referral Model GP to Consultant Self-referral to private clinic
Why "Evidence-Focused" Matters
Ever notice how if we want to see this form of treatment integrated more broadly, we have to move away from the "miracle" narrative. Medical cannabis—including Cannabidiol (CBD) and Tetrahydrocannabinol (THC) products—should be held to the same standard as any other pharmaceutical. That means acknowledging that it works for some and not for others. It means tracking efficacy through rigorous data collection. It means understanding that the clinical conversation is the only way to build long-term legitimacy.
The digital-first nature of private clinics has allowed for this data collection on a scale that wasn't possible before. By recording video consultations and tracking patient progress via digital apps, clinics are contributing to the growing evidence base. This is exactly what the medical community needs to see if we are ever going to move past the initial phase of skepticism.
Conclusion: Where Do We Go From Here?
We are in a transitional period. The 2018 regulations were the starting line, but we are still learning how to run the race. The clinical conversation is stronger, more precise, and more evidence-focused than it was five years ago. Exactly.. However, the access gap between those who can afford private care and those who cannot remains a pressing issue for patient advocates.
The rise of Telehealth platforms and the integration of video consultations have proven that we can deliver specialist care for complex, long-term conditions effectively and safely. The challenge now is to bridge the gap between this private innovation and the broader NHS system. Until then, patients will continue to navigate a split landscape, but at least the language we use to navigate it is finally rooted in science rather than newsroompanama.com stigma.